Vanguard Global Advisers
MLYS icon

Vanguard Global Advisers’s Mineralys Therapeutics MLYS Stock Holding History

Vanguard Global Advisers’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$750K Sell
27,783
-2,691
-9% -$73.8K ﹤0.01% 1917
2026
Q1 		$826K Buy
+30,474
New +$894K ﹤0.01% 1763

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Global Advisers's MLYS Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Mineralys Therapeutics (MLYS) stake by 8.8% in Q2 2026, selling an estimated $73.8K and leaving 27,783 shares worth $750K. The position accounts for ﹤0.01% of the portfolio, ranked #1917.

Vanguard Global Advisers first reported a position in MLYS in Q1 2026 and has held it in 2 quarters since. The position peaked at $826K in Q1 2026. 225 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Vanguard Global Advisers held 27,783 shares of Mineralys Therapeutics worth $750K as of Q2 2026.
  • Vanguard Global Advisers sold 2,691 Mineralys Therapeutics shares in Q2 2026, an estimated $73.8K.
  • Mineralys Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1917 holding.
  • Vanguard Global Advisers first reported a position in Mineralys Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Mineralys Therapeutics position peaked at $826K in Q1 2026.
  • 225 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.